etoposide has been researched along with sirolimus in 53 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (3.77) | 18.2507 |
2000's | 13 (24.53) | 29.6817 |
2010's | 34 (64.15) | 24.3611 |
2020's | 4 (7.55) | 2.80 |
Authors | Studies |
---|---|
Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
Cai, W; Hao, Y; Hu, P; Ma, D; Pan, H; Xie, X; Yu, AD; Yu, J; Yuan, J; Zhang, L; Zhu, H | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Ann, J; Jang, J; Kim, C; Kim, JH; Kim, S; Kim, SE; Kim, WK; Koh, Y; Lee, J; Lee, S; Moon, HS; Tran, PT; Yoon, S | 1 |
Ann, J; Jang, J; Kim, JH; Kim, S; Kim, WK; Koh, Y; Lee, J; Lee, S; Tran, PT; Yoon, I; Yoon, S | 1 |
Ann, J; Cho, D; Kim, JH; Kim, S; Kim, SE; Kim, WK; Lee, J; Lee, S; Yoon, I; Yoon, S; Zuo, D | 1 |
Liu, Y; Xu, Z; Zhao, SJ | 1 |
Bushell, M; McKendrick, L; Morley, SJ | 1 |
Bushell, M; Clemens, MJ; Morley, SJ | 1 |
Cotter, TG; Knox, KA; McGahon, AJ; McKenna, SL; O'Gorman, DM | 1 |
Carroll, M; Thompson, JE; Xu, Q | 1 |
Argentieri, D; Falotico, R; Parry, TJ; Siekierka, J; Tallarida, RJ; Thyagarajan, R | 1 |
Clutter, SD; Fortney, JE; Gibson, LF | 1 |
Cohen, RB; Dahlberg, S; Hidalgo, M; Johnson, DH; Lee, MW; Pandya, KJ; Schiller, JH | 1 |
Marik, PE; Vahid, B | 1 |
Arcaro, A; Dhillon, T; Lane, HA; Lemoine, NR; Marinov, M; Mauri, FA; Pardo, OE; Seckl, MJ; Tan, LT; Zangemeister-Wittke, U; Ziogas, A | 1 |
Akkaya, E; Macaulay, VM; Peak, S; Protheroe, AS; Sullivan, M; Takiguchi, M; Wang, Y; Yuen, JS | 1 |
Farkas, T; Høyer-Hansen, M; Jäättelä, M | 1 |
Bagg, A; Carroll, M; Dierov, JK; Frey, NV; Gewirtz, AM; Goldstein, SC; Hexner, EO; Kasner, MT; Loren, AW; Luger, SM; Nasta, SD; Perl, AE; Porter, DL; Schuster, SJ; Stadtmauer, EA; Swider, CR; Tsai, DE; Vogl, DT | 1 |
Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D | 1 |
Kiewe, P; Thiel, E | 1 |
Houghton, PJ; Kang, MH; Keshelava, N; Morton, CL; Reynolds, CP; Smith, MA | 1 |
He, XX; Huang, JJ; Huang, Y; Li, ZM; Lin, TY; Tian, Y; Xiao, J | 1 |
Wesierska-Gadek, J | 1 |
Blagosklonny, MV; Leontieva, OV | 1 |
Harada, T; Itamochi, H; Kigawa, J; Naniwa, J; Nonaka, M; Oishi, T; Sato, S; Shimada, M; Terakawa, N; Uegaki, K | 1 |
Abrams, SL; Chappell, WH; Drobot, LB; Franklin, RA; Libra, M; Martelli, AM; McCubrey, JA; Nicoletti, F; Sokolosky, ML; Stadelman, KM; Steelman, LS; Stivala, F | 1 |
Farkas, T; Frankel, LB; Høyer-Hansen, M; Jäättelä, M; Krogh, A; Lees, M; Lund, AH; Wen, J | 1 |
Carroll, M; Kasner, MT; Luger, SM; Perl, AE; Shank, D | 1 |
Levis, M | 1 |
Aurlien, E; Baggerød, E; Bishop, MR; Brinch, L; Dybedal, I; Egeland, T; Fløisand, Y; Fosså, A; Fowler, DH; Gedde-Dahl, T; Heldal, D; Holte, H; Kolstad, A; Kvalheim, G; Lauritzsen, GF; Lehne, G; Tjønnfjord, GE; Torfoss, D | 1 |
Attayan, N; Li, Z; Ramalingam, S; Thiele, CJ; Yan, S | 1 |
Alaggio, R; Bisogno, G; Cecchetto, G; Cheng, L; d'Amore, ES; Dall'Igna, P; Martignoni, G; Sperlì, D | 1 |
Couvelard, A; de Gramont, A; Faivre, S; Hammel, P; Neuzillet, C; Raymond, E; Serova, M; Tijeras-Raballand, A | 1 |
Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
Chen, R; Chen, X; Guo, J; Hu, Z; Liu, Z; Peng, H; Wang, Y; Zhang, H | 1 |
Beck, JT; Besse, B; Camidge, DR; Dimitrijevic, S; Heist, RS; Johnson, BE; Miller, N; Mulatero, C; Papadmitrakopoulou, VA; Petrovic, K; Pylvaenaeinen, I; Schmid, P; Urva, S | 1 |
Assavalapsakul, W; Chung, YH; Johnston, RN; Kaewpiboon, C; Koh, SS; Malilas, W; Moon, J; Phuwapraisirisan, P; Surapinit, S; Tip-Pyang, S | 1 |
Connis, N; Cope, L; Dobromilskaya, I; Gallia, GL; Gardner, EE; Hann, CL; Poirier, JT; Rudin, CM | 1 |
Eberle, C; Guttek, K; Hartig, R; Heiserich, L; Hiemann, R; Lorenz, S; Peters, V; Reddig, A; Reinhold, D; Roggenbuck, D; Sack, U; Schierack, P | 1 |
Kimura, S; Kobayashi-Watanabe, N; Sato, A; Sueoka, E; Sueoka-Aragane, N; Watanabe, T | 1 |
Huang, RC; Kimura, K | 1 |
Akeno, N; Callahan, M; He, D; Kim, RG; Lane, A; Miller, AL; Moulton, JS; Reece, AL; Wikenheiser-Brokamp, KA | 1 |
Carabasi, M; Carroll, M; Filicko-O'Hara, J; Flomenberg, N; Frey, NV; Hexner, EO; Jeschke, GR; Kasner, MT; Loren, AW; Luger, SM; Mangan, JK; Mick, R; Perl, AE; Wagner, JL; Weiss, M | 1 |
Blokland, KEC; Burgess, JK; Grainge, C; Hogaboam, CM; Jaffar, J; Khalil, N; Knight, DA; Mutsaers, SE; Pechkovsky, DV; Prêle, CM; Read, J; Reid, AT; Schuliga, M; Waters, DW; Westall, G | 1 |
Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
Cash, T; Goldsmith, KC; Katzenstein, HM; Kean, L; MacDonald, TJ; Qayed, M; Suessmuth, Y; Tanos, R; Tighiouart, M; Watkins, B; Wetmore, C | 1 |
Dowlati, A; Finigan, JH; Foster, DG; Gardner, EE; Kern, JA; Kim, J; Mishra, R; Poirier, JT; Rivard, C; Rudin, CM; Tan, AC; Yu, H | 1 |
Bateman, CM; Chi, YY; Cooper, TM; Gaynon, PS; Hutchinson, RJ; Laetsch, TW; Loftus, JP; Malvar, J; Orgel, E; Rheingold, SR; Schafer, ES; Schultz, KR; Silverman, LB; Sposto, R; Sulis, ML; Tasian, SK; Wayne, AS; Whitlock, JA | 1 |
Arancibia, Y; Castro-Guarda, M; Chipón, C; Matamala, C; Morera, FJ; Oyarzo, P; Reyes, A; Salas, M; Vargas, G; Zambrano, A | 1 |
5 review(s) available for etoposide and sirolimus
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Pulmonary complications of novel antineoplastic agents for solid tumors.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Everolimus; Gemcitabine; Humans; Lung; Lung Diseases; Mitoxantrone; Neoplasms; Pneumonia; Pyrimidines; Risk Factors; Sirolimus; Teniposide; Trastuzumab | 2008 |
Malignant perivascular epithelioid cell tumor in children: description of a case and review of the literature.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Child, Preschool; Combined Modality Therapy; Diagnostic Errors; Etoposide; Female; Humans; Imatinib Mesylate; Intestinal Obstruction; Ligaments; Liver Neoplasms; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Perivascular Epithelioid Cell Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Sarcoma, Clear Cell; Sirolimus; X Chromosome Inactivation | 2012 |
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Medical Oncology; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
10 trial(s) available for etoposide and sirolimus
Article | Year |
---|---|
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Remission Induction; Sirolimus; Survival Rate; Treatment Outcome | 2007 |
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Protein Kinases; Recurrence; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2009 |
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Phosphorylation; Pilot Projects; Ribosomal Protein S6; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vincristine; Young Adult | 2012 |
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Everolimus; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Sirolimus; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Mitoxantrone; Phosphorylation; Pilot Projects; Remission Induction; Signal Transduction; Sirolimus | 2018 |
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Topics: Administration, Metronomic; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Sirolimus; Young Adult | 2020 |
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001).
Topics: Adolescent; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Etoposide; Humans; MTOR Inhibitors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sirolimus; TOR Serine-Threonine Kinases | 2022 |
38 other study(ies) available for etoposide and sirolimus
Article | Year |
---|---|
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
Topics: Autophagy; Calcium Channel Blockers; Cell Line, Tumor; Drug Evaluation, Preclinical; Fluspirilene; Glioblastoma; Green Fluorescent Proteins; Humans; Intracellular Membranes; Loperamide; Microtubule-Associated Proteins; Mycotoxins; Peptides; Phagosomes; Phosphatidylinositol Phosphates; Pimozide; Protein Kinases; Recombinant Fusion Proteins; Sirolimus; Small Molecule Libraries; TOR Serine-Threonine Kinases; Trifluoperazine; Zinc Fingers | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Leucine; Leucine-tRNA Ligase; Mechanistic Target of Rapamycin Complex 1; Molecular Structure; Multiprotein Complexes; Structure-Activity Relationship; TOR Serine-Threonine Kinases | 2016 |
Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors.
Topics: Cell Line, Tumor; Drug Discovery; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Leucine-tRNA Ligase; Mass Spectrometry; Mechanistic Target of Rapamycin Complex 1; Phosphorylation; Proton Magnetic Resonance Spectroscopy; Ribosomal Protein S6 Kinases; Sulfonic Acids | 2017 |
Discovery of novel leucyladenylate sulfamate surrogates as leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Leucine; Leucine-tRNA Ligase; Mechanistic Target of Rapamycin Complex 1; Molecular Structure; Structure-Activity Relationship | 2018 |
Cleavage of translation initiation factor 4G (eIF4G) during anti-Fas IgM-induced apoptosis does not require signalling through the p38 mitogen-activated protein (MAP) kinase.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Arsenites; Calcium-Calmodulin-Dependent Protein Kinases; Caspase Inhibitors; Cell Survival; Etoposide; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4G; fas Receptor; Humans; Imidazoles; Immunoglobulin M; Jurkat Cells; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Peptide Initiation Factors; Phosphorylation; Poly(A)-Binding Proteins; Protein Biosynthesis; Pyridines; RNA-Binding Proteins; Signal Transduction; Sirolimus | 1998 |
Degradation of eukaryotic polypeptide chain initiation factor (eIF) 4G in response to induction of apoptosis in human lymphoma cell lines.
Topics: Amino Acid Chloromethyl Ketones; Antibodies; Apoptosis; Caspase Inhibitors; Caspases; Culture Media, Serum-Free; Cycloheximide; Etoposide; Eukaryotic Initiation Factor-4E; fas Receptor; Half-Life; Humans; Jurkat Cells; Lymphoma; Molecular Weight; Neoplasm Proteins; Oligopeptides; Peptide Initiation Factors; Poly(A)-Binding Proteins; Poly(ADP-ribose) Polymerases; Protein Synthesis Inhibitors; RNA-Binding Proteins; Sirolimus; Tumor Cells, Cultured | 1998 |
Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals.
Topics: Androstadienes; Antineoplastic Agents; Apigenin; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Camptothecin; Carrier Proteins; Cell Survival; Chromones; Cycloheximide; Dactinomycin; Dimerization; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Flavonoids; Genes, bcl-2; HL-60 Cells; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mitoxantrone; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Sirolimus; Wortmannin | 2000 |
mTOR regulates cell survival after etoposide treatment in primary AML cells.
Topics: Animals; Cell Survival; Culture Media; Etoposide; Humans; Leukemia, Myeloid, Acute; Mice; Protein Kinases; Sirolimus; Stem Cells; Time Factors; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2005 |
Effects of drug combinations on smooth muscle cell proliferation: an isobolographic analysis.
Topics: Algorithms; Cell Proliferation; Cell Survival; Cells, Cultured; Cladribine; Coronary Vessels; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Growth Inhibitors; Humans; Myocytes, Smooth Muscle; Sirolimus; Topotecan | 2006 |
Chemotherapy disrupts activity of translational regulatory proteins in bone marrow stromal cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cell Cycle Proteins; Cell Line; Cyclophosphamide; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Etoposide; Humans; Matrix Metalloproteinase 2; Melphalan; Mice; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Ribosomal Protein S6; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Stromal Cells; Structure-Activity Relationship; TOR Serine-Threonine Kinases | 2006 |
AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
Topics: Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Etoposide; Everolimus; Humans; Lung Neoplasms; Mice; Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sirolimus; Stem Cell Factor; TOR Serine-Threonine Kinases | 2009 |
Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Receptor, IGF Type 1; RNA, Small Interfering; Sirolimus; Transfection; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2009 |
Identification of novel autophagy regulators by a luciferase-based assay for the kinetics of autophagic flux.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biological Assay; Cells, Cultured; Enzyme Inhibitors; Etoposide; Fibroblasts; Genes, Reporter; Humans; Luciferases; Membrane Proteins; Mice; Microtubule-Associated Proteins; Recombinant Fusion Proteins; RNA, Small Interfering; Sirolimus | 2009 |
Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednisolone; Remission Induction; Sirolimus; Tongue Neoplasms; Treatment Failure; Treatment Outcome; Vincristine | 2011 |
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Topics: Antineoplastic Agents; Cell Line, Tumor; Child; Drug Screening Assays, Antitumor; Etoposide; Humans; Melphalan; National Cancer Institute (U.S.); Sirolimus; United States; Vincristine | 2011 |
Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Everolimus; Humans; Jurkat Cells; Lymphoma, T-Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazines; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Vincristine | 2012 |
mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging.
Topics: Animals; Cell Cycle; Cell Proliferation; Cell Shape; Cellular Senescence; DNA Damage; Doxorubicin; Enzyme Activation; Etoposide; Humans; Imidazoles; Piperazines; Protein Kinase Inhibitors; Serum; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Up-Regulation | 2010 |
DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
Topics: Cell Cycle; Cell Line; Cell Proliferation; Cell Shape; Cellular Senescence; DNA Damage; Doxorubicin; Enzyme Activation; Etoposide; Humans; Imidazoles; Neoplasms; Piperazines; Protein Kinase Inhibitors; Retinal Pigment Epithelium; Serum; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Up-Regulation | 2010 |
Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Proto-Oncogene Proteins c-jun; Signal Transduction; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Molecular Targeted Therapy; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases | 2011 |
microRNA-101 is a potent inhibitor of autophagy.
Topics: Autophagy; Autophagy-Related Proteins; Breast Neoplasms; Cell Line, Tumor; Cysteine Endopeptidases; Etoposide; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; rab5 GTP-Binding Proteins; RNA Interference; RNA, Small Interfering; Sirolimus; Stathmin; Tamoxifen | 2011 |
Phospho-specific flow: fixating on the target.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Ribosomal Protein S6; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.
Topics: Allosteric Regulation; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Etoposide; Female; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neuroblastoma; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sirolimus; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
MTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB1.
Topics: Animals; Apoptosis; Autophagy; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; DNA Damage; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Humans; MCF-7 Cells; Mice; Mice, Transgenic; Rats; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Feroniellin A-induced autophagy causes apoptosis in multidrug-resistant human A549 lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; Autophagy; Beclin-1; Cell Line, Tumor; Coumarins; Drug Resistance, Neoplasm; Etoposide; Furans; Glycosides; Humans; Lung Neoplasms; Membrane Proteins; Microfilament Proteins; Nitriles; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Sirolimus; Sulfones; Transcription Factor RelA; Transcription, Genetic | 2014 |
Rapamycin rescues ABT-737 efficacy in small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cell Line, Tumor; Drug Synergism; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, SCID; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Sirolimus; Small Cell Lung Carcinoma; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Assessment of modulated cytostatic drug resistance by automated γH2AX analysis.
Topics: Adult; Cyclosporine; Cytostatic Agents; DNA; DNA Breaks, Double-Stranded; Drug Resistance, Multiple; Etoposide; Female; Histones; Humans; Leukocytes, Mononuclear; Male; Microscopy, Fluorescence; Sirolimus; Young Adult | 2015 |
Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Etoposide; G1 Phase Cell Cycle Checkpoints; Humans; Leukemia-Lymphoma, Adult T-Cell; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Naphthyridines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2016 |
Tetra-O-Methyl Nordihydroguaiaretic Acid Broadly Suppresses Cancer Metabolism and Synergistically Induces Strong Anticancer Activity in Combination with Etoposide, Rapamycin and UCN-01.
Topics: Antineoplastic Agents; Autophagy; Carbohydrate Metabolism; Caspase 7; Cell Line, Tumor; Down-Regulation; Drug Synergism; Energy Metabolism; Etoposide; Glutathione; Humans; Lipid Metabolism; Male; Masoprocol; Metabolic Networks and Pathways; Metabolome; Neoplasms; Oxidative Stress; Reactive Oxygen Species; Sirolimus; Staurosporine | 2016 |
TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neuroendocrine Tumors; Sirolimus; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53 | 2017 |
Mitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblasts.
Topics: Acetylcysteine; Biomarkers; Cellular Senescence; Cyclic N-Oxides; Down-Regulation; Etoposide; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Lung; Mitochondria; Myofibroblasts; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rotenone; Sirolimus | 2018 |
Role of mTOR As an Essential Kinase in SCLC.
Topics: Cisplatin; Etoposide; Humans; Lung Neoplasms; Sirolimus; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2020 |
Metabolic changes induced by DNA damage in Ramos cells: exploring the role of mTORC1 complex.
Topics: DNA Damage; Etoposide; Mechanistic Target of Rapamycin Complex 1; Sirolimus; TOR Serine-Threonine Kinases | 2022 |